4//SEC Filing
Khan Samina 4
Accession 0001209191-23-016306
CIK 0001358762other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:40 PM ET
Size
15.6 KB
Accession
0001209191-23-016306
Insider Transaction Report
Form 4
Khan Samina
SVP, Chief Medical Officer
Transactions
- Exercise/Conversion
Class A common stock
2023-03-02$27.32/sh+25,000$683,000→ 71,905 total - Sale
Class A common stock
2023-03-02$83.70/sh−3,395$284,162→ 68,510 total - Sale
Class A common stock
2023-03-02$85.02/sh−18,956$1,611,639→ 49,554 total - Sale
Class A common stock
2023-03-02$85.38/sh−2,649$226,172→ 46,905 total - Sale
Class A common stock
2023-03-03$87.36/sh−2,813$245,744→ 44,092 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-03-02−25,000→ 25,000 totalExercise: $27.32Exp: 2032-01-03→ Class A common stock (25,000 underlying)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $83.26 to $84.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.26 to $85.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.26 to $85.58. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $87.36 to $87.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]The options began vesting in sixteen equal installments beginning on April 3, 2022. On February 28, 2023, based on the satisfaction of certain performance criteria, the options scheduled to vest on April 3, 2025, July 3, 2025, October 3, 2025, and January 3, 2026 vested immediately. The remainder of the vesting schedule will continue as originally stated, subject to continued service through each vesting date.
Documents
Issuer
REATA PHARMACEUTICALS INC
CIK 0001358762
Entity typeother
Related Parties
1- filerCIK 0001903865
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:40 PM ET
- Size
- 15.6 KB